已发表论文

前列腺癌患者放疗后继发性膀胱癌患病率高:综合分析所产生的证据

 

Authors Zhao S, Xie Q, Yang R, Wang J, Zhang C, Luo L, Zhu Z, Liu Y, Li E, Zhao Z

Received 30 August 2018

Accepted for publication 13 November 2018

Published 10 January 2019 Volume 2019:11 Pages 587—598

DOI https://doi.org/10.2147/CMAR.S185867

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr Chien-Feng Li

Objective: To assess whether radiotherapy (RT) for prostate cancer (PCa) was a risk factor for secondary bladder cancer (BLCa) through a meta-analysis.
Materials and methods: The MEDLINE, Embase, and the Cochrane Library were systematically searched for all studies investigating the risk of BLCa in patients with RT. The association between RT and risk of BLCa was summarized using hazard ratio with a 95%CI. The protocol for this meta-analysis is available from PROSPERO (CRD42018090075).
Results: Overall, 619,479 participants (age: 57–79 years) were included from 15 studies, 206,852 of whom were patients who received RT. Synthesis of results indicated that RT was significantly associated with an increased risk of BLCa compared with the risk in those who received radical prostatectomy or non-RT (overall HR=1.6, 95%CI: 1.33–1.92, <0.001). The results were consistent when restricted to a 5-year lag period (HR=1.84, 95%CI: 1.26–2.69, =0.002) and multivariable adjustment (HR=1.96, 95%CI: 1.47–2.62, <0.001), but not for 10-year lag period (HR=1.93, 95%CI: 0.9– 4.16, =0.093) and brachytherapy subgroup (HR=1.33, 95%CI: 0.87–2.05, =0.188). The GRADE-profiler revealed that the rate of events of BLCa on average in the RT-patients and the non-RT control was 2,462/183,669 (1.3%) and 4,263/382,761(1.1%), respectively; the overall quality of the evidence was low.
Conclusion: Patients who received RT for PCa was associated with higher risks of developing secondary BLCa compared to those unexposed to RT, but the absolute effect was low.
Keywords: prostate cancer, radiation, radiotherapy, secondary bladder cancer, radical prostatectomy




Figure 1 Flow chart of study selection.